• Locations
  • Conditions
  • Treatments
  • Institutions
  • Resources
  • For researchers
  • About us
Facebook link logoLinkedin link logo
Terms of usePrivacy policy
All Clinical Trials 2026All Rights reservedPrivacy PolicyTerms of Use
LocationsTexasArizonaCaliforniaNew YorkMassachusettsFloridaNew JerseyUtahAll locationsConditionsOncologyAlzheimer'sDiabetesMultiple SclerosisArthritisHepatitis CCOPDDepressionAll conditionsTreatmentsWeight LossStem CellsVaccinesSleep ApneaMedical DevicesIVFDentalDrug AddictionAll treatmentsInstitutionsPfizerModernaNIHUCLAStanfordM.D. AndersonLabcorpAll institutionsResourcesBlogFAQMedical advisors
Terms of usePrivacy policy
All Clinical Trials 2026All Rights reservedPrivacy PolicyTerms of Use
  1. Clinical trials
  2. Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)
  3. Apply

Bortezomib & CPX-351Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)

Basic information
Step 1/5

Provide your basic information